Search Results - "Reisewitz, Pascal"

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Long-term outcomes of elosulfase alfa enzyme replacement therapy in adults with MPS IVA: a sub-analysis of the Morquio A Registry Study (MARS).

    Authors: Stepien, Karolina M. Burton, Barbara K. Bober, Michael B. et al.

    Source: Orphanet Journal of Rare Diseases. 10/30/2025, Vol. 20 Issue 1, p1-10. 10p.

    HTML Full Text PDF Full Text
    Save to List
  2. 2

    This result is not displayed to guests.

    Save to List
  3. 3

    Real-world impact of enzyme replacement therapy on endurance in patients with MPS IVA.

    Authors: Reisewitz, Pascal Hinds, David Dosenovic, Sara et al.

    Source: Molecular Genetics & Metabolism. Feb2023, Vol. 138 Issue 2, pN.PAG-N.PAG. 1p.

    Save to List
  4. 4

    Improvements in quality of life outcomes among individuals with MPS IVA treated with elosulfase alfa: Results from the Morquio A Registry Study (MARS).

    Authors: Campeau, Philippe M. Burton, Barbara K. Ellaway, Carolyn et al.

    Source: Molecular Genetics & Metabolism. Feb2026, Vol. 147 Issue 2, pN.PAG-N.PAG. 1p.

    Save to List
  5. 5

    Seizures and movement disorders in patients with CLN2 disease treated with cerliponase alfa in the real-world setting.

    Authors: Schulz, Angela Nickel, Miriam Schwering, Christoph et al.

    Source: Molecular Genetics & Metabolism. Feb2025, Vol. 144 Issue 2, pN.PAG-N.PAG. 1p.

    Save to List
  6. 6

    Real-world clinical outcomes of patients with CLN2 disease treated with cerliponase alfa.

    Authors: Schulz A Schwering C Wibbeler E et al.

    Source: Frontiers in neurology [Front Neurol] 2025 Mar 14; Vol. 16, pp. 1516026. Date of Electronic Publication: 2025 Mar 14 (Print Publication: 2025).

    Publication Type: Journal Article

    Journal Info: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101546899 Publication Model: eCollection Cited Medium: Print ISSN: 1664-2295 (Print) Linking ISSN: 16642295 NLM ISO Abbreviation: Front Neurol Subsets: PubMed not MEDLINE

    HTML Full Text PDF Full Text
    Save to List
  7. 7

    Real-world treatment with elosulfase alfa in patients with MPS IVA is associated with improved endurance over time.

    Authors: Burton BK Stepien KM Campeau PM et al.

    Source: Genetics in medicine open [Genet Med Open] 2025 Mar 29; Vol. 3, pp. 103428. Date of Electronic Publication: 2025 Mar 29 (Print Publication: 2025).

    Publication Type: Journal Article

    Journal Info: Publisher: Elsevier Inc Country of Publication: United States NLM ID: 9918734281906676 Publication Model: eCollection Cited Medium: Internet ISSN: 2949-7744 (Electronic) Linking ISSN: 29497744 NLM ISO Abbreviation: Genet Med Open Subsets: PubMed not MEDLINE

    Save to List
  8. 8

    Discrete shoot and root stem cell-promoting WUS/WOX5 functions are an evolutionary innovation of angiosperms.

    Authors: Nardmann J Reisewitz P Werr W

    Source: Molecular biology and evolution [Mol Biol Evol] 2009 Aug; Vol. 26 (8), pp. 1745-55. Date of Electronic Publication: 2009 Apr 22.

    Publication Type: Journal Article; Research Support, Non-U.S. Gov't

    Journal Info: Publisher: Oxford University Press Country of Publication: United States NLM ID: 8501455 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1537-1719 (Electronic) Linking ISSN: 07374038 NLM ISO Abbreviation: Mol Biol Evol Subsets: MEDLINE

    PDF Full Text
    Save to List

Search Tools: